tetano
Editor, Senior Moderator
Front Immunol
. 2024 Nov 25:15:1465238.
doi: 10.3389/fimmu.2024.1465238. eCollection 2024. Immunophenotyping characteristics and clinical outcome of COVID-19 patients treated with azvudine during the Omicron surge
Meihua Qiu[SUP] #[/SUP][SUP] 1 2 [/SUP], Xiaogang Song[SUP] #[/SUP][SUP] 1 [/SUP], Qianqian Zhang[SUP] #[/SUP][SUP] 3 [/SUP], Shenchun Zou[SUP] 1 [/SUP], Lingling Pang[SUP] #[/SUP][SUP] 1 [/SUP], Xueyuan Nian[SUP] #[/SUP][SUP] 4 [/SUP]
Affiliations
Background: Little is known about immunophenotyping characteristics and clinical outcomes of COVID-19 patients treated with azvudine during the Omicron variant surge.
Methods: This study enrolled patients diagnosed with COVID-19 from December 2022 to February 2023. The primary outcome was defined as all-cause mortality, along with a composite outcome reflecting disease progression. The enrolled patients were followed for a period of 60 days from their admission.
Results: A total of 268 COVID-19 patients treated with azvudine were enrolled in this retrospective study. The study found that the counts of lymphocyte subsets were significantly reduced in the composite outcome and all-cause mortality groups compared to the non-composite outcome and discharge groups (all p < 0.001). Correlation analysis revealed a negative association between lymphocyte subsets cell counts and inflammatory markers levels. The receiver operating characteristic (ROC) curve analysis identified low CD4[SUP]+[/SUP] T cell count as the most significant predictor of disease progression and all-cause mortality among the various lymphocyte subsets. Additionally, both the Kaplan-Meier curve and multivariate regression analysis demonstrated that low CD4[SUP]+[/SUP] T cell count level (< 156.00 cells/μl) was closely associated with all-cause mortality in COVID-19 patients treated with azvudine.
Conclusions: A low CD4[SUP]+[/SUP] T cell count may serve as a significant predictive indicator for identifying COVID-19 patients receiving azvudine treatment who are at an elevated risk of experiencing adverse outcomes. These findings may offer valuable insights for physicians in optimizing the administration of azvudine.
Keywords: CD4+ T cell; COVID-19; azvudine; lymphocyte subsets; mortality.
. 2024 Nov 25:15:1465238.
doi: 10.3389/fimmu.2024.1465238. eCollection 2024. Immunophenotyping characteristics and clinical outcome of COVID-19 patients treated with azvudine during the Omicron surge
Meihua Qiu[SUP] #[/SUP][SUP] 1 2 [/SUP], Xiaogang Song[SUP] #[/SUP][SUP] 1 [/SUP], Qianqian Zhang[SUP] #[/SUP][SUP] 3 [/SUP], Shenchun Zou[SUP] 1 [/SUP], Lingling Pang[SUP] #[/SUP][SUP] 1 [/SUP], Xueyuan Nian[SUP] #[/SUP][SUP] 4 [/SUP]
Affiliations
- PMID: 39654887
- PMCID: PMC11625784
- DOI: 10.3389/fimmu.2024.1465238
Background: Little is known about immunophenotyping characteristics and clinical outcomes of COVID-19 patients treated with azvudine during the Omicron variant surge.
Methods: This study enrolled patients diagnosed with COVID-19 from December 2022 to February 2023. The primary outcome was defined as all-cause mortality, along with a composite outcome reflecting disease progression. The enrolled patients were followed for a period of 60 days from their admission.
Results: A total of 268 COVID-19 patients treated with azvudine were enrolled in this retrospective study. The study found that the counts of lymphocyte subsets were significantly reduced in the composite outcome and all-cause mortality groups compared to the non-composite outcome and discharge groups (all p < 0.001). Correlation analysis revealed a negative association between lymphocyte subsets cell counts and inflammatory markers levels. The receiver operating characteristic (ROC) curve analysis identified low CD4[SUP]+[/SUP] T cell count as the most significant predictor of disease progression and all-cause mortality among the various lymphocyte subsets. Additionally, both the Kaplan-Meier curve and multivariate regression analysis demonstrated that low CD4[SUP]+[/SUP] T cell count level (< 156.00 cells/μl) was closely associated with all-cause mortality in COVID-19 patients treated with azvudine.
Conclusions: A low CD4[SUP]+[/SUP] T cell count may serve as a significant predictive indicator for identifying COVID-19 patients receiving azvudine treatment who are at an elevated risk of experiencing adverse outcomes. These findings may offer valuable insights for physicians in optimizing the administration of azvudine.
Keywords: CD4+ T cell; COVID-19; azvudine; lymphocyte subsets; mortality.